A global equity firm well-versed in pharmaceutical investing is betting the ongoing frenzy in weight-loss drug stock has further to run.
Novo Nordisk and Eli Lilly are among top holdings in the A$1.3 billion Capital Group New Perspective Fund, which is beating 94 per cent of peers this year, according to data compiled by Bloomberg. The long-standing fund, which first invested in the two companies long before recent fervour for obesity treatments, claims ...
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: